Arcturus Therapeutics Holdings Inc. Stock News

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Preclinical Da

An analyst downgraded the biotech stock.

Nothing compares to these companies.

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

They each have a key competitive edge that could set them apart.

The first to market won't necessarily dominate the market over the long run.

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

There's something for every kind of investor with this list.

A biotech that no one has heard of has been making a few investors rich for much of 2020.

This could be the perfect time for aggressive investors to scoop up shares.

This can happen when a company holds out its hand for a big chunk of fresh capital.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious dis

Don't be surprised if this small biotech takes off in 2021.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Piper Sandler's 32nd Annual Virtual Healthcare Conference